Filing Details

Accession Number:
0001209191-23-043986
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-01 16:29:51
Reporting Period:
2023-07-28
Accepted Time:
2023-08-01 16:29:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1688712 Carter Dawn Bir 5320 Legacy Dr.
Plano TX 75024
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2023-07-28 40,000 $0.00 75,010 No 4 C Direct
Class A Common Stock Disposition 2023-07-28 40,000 $164.54 35,010 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class B Common Stock Employee Stock Option (right to buy) Disposition 2023-07-28 40,000 $0.00 40,000 $22.57
Class A Common Stock Class B common stock Acquisiton 2023-07-28 40,000 $22.57 40,000 $0.00
Class A Common Stock Class B common stock Disposition 2023-07-28 40,000 $0.00 40,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2026-12-07 No 4 M Direct
40,000 No 4 M Direct
0 No 4 C Direct
Footnotes
  1. The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $165.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The options vested in twenty equal quarterly installments beginning on March 7, 2017.